99 related articles for article (PubMed ID: 12565723)
41. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model.
Walenga JM; Fareed J; Petitou M; Samama M; Lormeau JC; Choay J
Thromb Res; 1986 Jul; 43(2):243-8. PubMed ID: 3738864
[No Abstract] [Full Text] [Related]
42. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.
Spanier TB; Oz MC; Minanov OP; Simantov R; Kisiel W; Stern DM; Rose EA; Schmidt AM
J Thorac Cardiovasc Surg; 1998 May; 115(5):1179-88. PubMed ID: 9605089
[TBL] [Abstract][Full Text] [Related]
43. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Hollenbach S; Sinha U; Lin PH; Needham K; Frey L; Hancock T; Wong A; Wolf D
Thromb Haemost; 1994 Mar; 71(3):357-62. PubMed ID: 8029801
[TBL] [Abstract][Full Text] [Related]
44. Lack of correlation between "in vitro" and "in vivo" antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent "in vivo".
Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP
Thromb Res; 1985 Dec; 40(5):597-607. PubMed ID: 4089830
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.
Krieter DH; Fink S; Dorsch O; Harenberg J; Melzer N; Wanner C; Lemke HD
Artif Organs; 2015 Nov; 39(11):951-9. PubMed ID: 25900127
[TBL] [Abstract][Full Text] [Related]
46. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
Lord H; Jean N; Dumont M; Kassis J; Leblanc M
Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
[TBL] [Abstract][Full Text] [Related]
47. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
48. Cardiovascular pharmacological studies on JTV-506, a new potassium channel opener. 1st communication: effects on myocardium and vasculature.
Hirata Y; Suzuki Y; Miyai H; Aisaka K
Arzneimittelforschung; 2000 Mar; 50(3):236-43. PubMed ID: 10758774
[TBL] [Abstract][Full Text] [Related]
49. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis.
Von Bonsdorff M; Stiekema J; Harjanne A; Alapiessa U
Int J Artif Organs; 1990 Feb; 13(2):103-8. PubMed ID: 2347652
[TBL] [Abstract][Full Text] [Related]
50. [Low molecular weight heparin (CY 222) levels during hemodialysis sessions. Comparison of various chromogenic and chronometric methods. Problem of standardization].
Roussel B; Dieval J; Bayrou B; Delobel J
J Mal Vasc; 1987; 12 Suppl B():85-9. PubMed ID: 2834499
[TBL] [Abstract][Full Text] [Related]
51. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
[TBL] [Abstract][Full Text] [Related]
52. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients].
Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555
[TBL] [Abstract][Full Text] [Related]
53. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.
Christidou FN; Frangia TK; Bamichas GI; Gionanlis LC; Natse TA; Georgoulis IE; Sombolos KI
Int J Clin Pharmacol Ther; 2005 Jul; 43(7):335-8. PubMed ID: 16035376
[TBL] [Abstract][Full Text] [Related]
54. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
[TBL] [Abstract][Full Text] [Related]
55. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
56. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
57. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
[TBL] [Abstract][Full Text] [Related]
58. Low molecular weight heparin in hemodialysis patients with a bleeding tendency.
Leu JG; Chiang SS; Lin SM; Pai JK; Jiang WW
Nephron; 2000 Dec; 86(4):499-501. PubMed ID: 11124600
[TBL] [Abstract][Full Text] [Related]
59. Vitamin E-Coated and Heparin-Coated Dialyzer Membranes for Heparin-Free Hemodialysis: A Multicenter, Randomized, Crossover Trial.
Islam MS; Hassan ZA; Chalmin F; Vido S; Berrada M; Verhelst D; Donnadieu P; Moranne O; Esnault VL
Am J Kidney Dis; 2016 Nov; 68(5):752-762. PubMed ID: 27344212
[TBL] [Abstract][Full Text] [Related]
60. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
